NEW YORK (Reuters Health) – A newly developed hemodialyzer membrane improves neutrophil function, oxidative stress, and LDL concentrations in patients with end-stage renal failure, according to a report by Japanese investigators.
In contrast to conventional membranes, the new membrane, produced by Tokyo-based Terumo Co. Ltd. under the name CL-EE, contains vitamin E. Previous findings have suggested improved dialysis outcomes with vitamin E-bonded membranes, but their superiority has not been established in definitive clinical trials, the authors note.
Dr. Shuichi Tsuruoka, from the Jichi Medical School, and colleagues performed a crossover study comparing the new membrane with a control dialyzer membrane in 10 patients with end-stage renal failure. The author's findings are reported in the January issue of the American Journal of Kidney Diseases.
On initial use, both membranes produced a similar degree of leukocytopenia. However, after repeated use, the reduction in white blood cells was less marked with the CL-EE membrane. In addition, superoxide anion levels were reduced with repeated use of the CL-EE membrane.
Repeated use of the CL-EE membrane produced less of an increase in oxidized LDL levels compared with repeated use of the control membrane. Furthermore, repeated use of the CL-EE membrane lead to a significant reduction in serum LDL concentrations.
The current findings indicate that the CL-EE membrane improves neutrophil function, oxidant stress, and serum lipid profiles, the authors state. "Use of this membrane may decrease cardiovascular events in patients with end-stage renal failure," they add.
Am J Kidney Dis 2002;39:127-133.